The therapeutic potential of aryl hydrocarbon receptor (AhR) agonists in anticancer drug development

Drugs of the Future

Volumn 29, Issue 5, 2004, Pages 479-491

  Westwell, Andrew D ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(5 AMINO 2,3 FLUOROPHENYL) 6,8 DIFLUORO 7 METHYL 4H 1 BENZOPYRAN 4 ONE; 1,3,8 TRICHLORO 6 METHYLDIBENZOFURAN; 2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; 2 (4 AMINO 3 METHYLPHENYL) 6 HYDROXYBENZOTHIAZOLE; 2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 2 (4 AMINOPHENYL)BENZOTHIAZOLE; 3 INDOLEMETHANOL; 5 AMINO 6,8 DIFLUORO 2 (3 FLUOROPHENYL) 7 METHYL 4H 1 BENZOPYRAN 4 ONE; 5F 203; AROMATIC HYDROCARBON RECEPTOR; BENZOTHIAZOLE DERIVATIVE; CYTOCHROME P450 1A1; DIAMINOFLAVONE; FLAVONE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CYTOTOXICITY; DIMERIZATION; DRUG EFFECT; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 3242881177     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.05.804556     Document Type: Review

References (91)

1. Schmidt, J.V., Bradfield, C.A. AH receptor signalling pathways. Annu Rev Cell Develop Biol 1996, 12: 55-89.
2. Landers, J.P., Bunce, N.J. The AH receptor and the mechanism of dioxin toxicity. Biochem J 1991, 276: 273-87.
3. Rowlands, C., Krishnan, V., Wang, X., Santostefano, M., Safe, S., Miller, W.R., Langdon, S. Characterization of the aryl hydrocarbon receptor and aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines. Cancer Res 1993, 53: 1802-7.
4. Safe, S., Astroff, B., Harris, M., Zacharweski, T., Dickerson, R., Romkes, M., Biegel, L. 2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD) and related compounds as antiestrogens - Characterization and mechanism of action. Pharmacol Toxicol 1991, 69: 400-9.
5. Poellinger, L., Lund, J., Gillner, M., Gustafson, J.-A. In: Molecular Mechanisms of Steroid Hormone Action. Moudgil, V.K. (Ed.). Walter de Gruyter & Co.: Berlin, 1985.
6. Burbach, K.M., Poland, A., Bradfield, C.A. Cloning of the AH-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA 1992, 89: 8185-9.
7. 2 tension. Proc Natl Acad Sci USA 1995, 92: 5510-4.
8. Bradshaw, T.D., Trapani, V., Vasselin, D.A., Westwell, A.D. The arylhydrocarbon receptor in anticancer drug discovery: Friend or foe? Curr Pharm Des 2002, 8: 2475-90.
9. Bradshaw, T.D., Mortimer, C.G., Westwell, A.D. Update to the arylhydrocarbon receptor in anticancer drug discovery: Friend or foe? Med Chem Rev 2004, Manuscript submitted.
10. Denison, M.S., Nagy, S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003, 43: 309-34.
11. Safe, S., Wormke, M. Inhibitory aryl hydrocarbon receptor-estrogen receptor α cross-talk and mechanisms of action. Chem Res Toxicol 2003, 16: 807-16.
12. Ma, Q. Induction of CYP1A1. The AhR/DRE paradigm: Transcription, receptor regulation, and expanding biological roles. Curr Drug Metab 2001, 2: 149-64.
13. Trapani, V. PhD thesis, University of Nottingham, U.K. 2003.
14. Rowlands, J.C., Gustaffson, J.-A. Aryl hydrocarbon-mediated signal transduction. Crit Rev Toxicol 1997, 27: 109-34.
15. Bell, D.R., Poland, A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein - The role of hsp90. J Biol Chem 2000, 275: 36407-14.
16. Whitlock, J.P. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999, 39: 103-25.
17. Williams, J.B., Wang, R., Lu, A.Y., Pickett, C.B. Rat liver DT-diaphorase: Regulation of functional mRNA levels by 3-methylcholanthrene, trans-stilbene oxide, and phenobarbital. Arch Biochem Biophys 1984, 232: 408-13.
18. Ma, Q., Whitlock, J.P. The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol Cell Biol 1996, 16: 2144-50.
19. Vaziri, C., Faller, D.V. A benzo[a]pyrene-induced cell cycle checkpoint resulting in p53-independent G1 arrest in 3T3 fibroblasts. J Biol Chem 1997, 272: 2762-9.
20. Weiss, C., Kolluri, S.K., Kiefer, F., Gottlicher, M. Complementation of Ah receptor deficiency in hepatoma cells: Negative feedback regulation and cell cycle control by the Ah receptor. Exp Cell Res 1996, 226: 154-63.
21. Puga, A., Xia, Y., Elferink, C. Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem-Biol Interact 2002, 141: 117-30.
22. Chan, W.K., Yao, G., Gu, Y.Z., Bradfield, C.A. Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways - Demonstration of competition and compensation. J Biol Chem 1999, 274: 12115-23.
23. Reiners, J.J., Clift, R.E. Aryl hydrocarbon receptor regulation of ceramide-induced apoptosis in murine hepatoma 1c1c7 cells - A function independent of aryl hydrocarbon receptor nuclear translocator. J Biol Chem 1999, 274: 2502-10.
24. Zaher, H., Fernandez-Salguero, P.M., Letterio, J., Sheikh, S.M., Fornace, A.J., Roberts, A.B., Gonzalez, F.J. The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis. Mol Pharmacol 1998, 54: 313-21.
25. Patterson, L.H., Murray, G.E. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002, 8: 1335-47.
26. Marinello, A.J., Bansal, S.K., Paul, B., Koser, P.L., Love, J., Struck, R.F., Gurtoo, H.L. Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450. Cancer Res 1984, 44: 4615-21.
27. Yu, L.J., Matias, J., Scudiero, D.A., Hite, K.M., Monks, A., Sausville, E.A., Waxman, D.J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 2001, 29: 304-12.
28. Yao, K.-S., O'Dwyer, P.J. Involvement of NF-κB in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. Biochem Pharmacol 1995, 49: 275-82.
29. Fitzsimmons, S.A., Workman, P., Grever, M., Paull, K., Camalier, R., Lewis, A.D. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and E09. J Natl Cancer Inst 1996, 88: 259-69.
30. Carlson, D.B., Perdew, G.H. A dynamic role for the Ah receptor in cell signalling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 2002, 16: 317-25.
31. Fernandez-Salguero, P.M., Hilbert, D.M., Rudikoff, S., Ward, J., Gonzalez, F.J. Aryl hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996, 140: 173-9.
32. Holcomb, M., Safe, S. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorobenzo-p-dioxin. Cancer Lett 1994, 82: 43-7.
33. Gierthy, J.F., Bennett, J.A., Bradley, L.M., Cutler, D.S. Correlation of in-vitro and in-vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 1993, 53: 3149-53.
34. Bertazzi, P.A., Pesatori, A.C., Consonni, D., Tironi, A., Landi, M.T., Zoccilietti, C. Cancer incidence in a population accidentally exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Epidemiology 1993, 4: 398-406.
35. Bertazzi, P.A., Bernucci, I., Brambilla, G., Consonni, D., Pesatori, A.C. The Seveso studies on early and long term effects of dioxin exposure: A review. Environ Health Perspect 1998, 106(Suppl. 2): 625-33.
36. Rogers, J.M., Denison, M.S. Analysis of the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human ovarian carcinoma BG-1 cells. Mol Pharmacol 2002, 61: 1393-403.
37. Ricci, M.S., Toscano, D.G., Mattingly, C.J., Toscano, W.A. Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells. J Biol Chem 1999, 274: 3430-8.
38. McDougal, A., Wormke, M., Calvin, J., Safe, S. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res 2001, 61: 3902-7.
39. Safe, S., Wormke, M., Samudio, I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol 2000, 5: 295-306.
40. McDougal, A., Sethi-Gupta, M., Ramamoorthy, K., Sun, G., Safe, S. Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett 2000, 151: 169-79.
41. Koliopanos, A., Kleeff, J., Xiao, Y., Safe, S., Zimmerman, A., Buchler, M.W., Friess, H. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene, 2002, 21: 6059-70.
42. McDougal, A., Wilson, C., Safe, S. Inhibition of 7,12-dimethylbenz[a] anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 1997, 120: 53-63.
43. Corton, J.C., Anderson, S.P., Stauber, A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000, 40: 491-518.
44. Watkins, R.E., Noble, S.M., Redinho, M.R. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Develop 2002, 5: 150-8.
45. Waller, C.L., McKinney, J.D. 3-Dimensional quantitative structure-activity relationships of dioxins and dioxin-like compounds - Model validation and AH receptor characterization. Chem Res Toxicol 1995, 8: 847-58.
46. Denison, M.S., Pandini, A., Nagy, S.R., Baldwin, E.P., Bonalti, L. Ligand binding and activation of the Ah receptor. Chem-Biol Interact 2002, 141: 3-24.
47. Petrulis, J.R., Perdew, G.H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem-Biol Interact 2002, 141: 25-40.
48. Bradlow, H.L., Sepkovic, D.W., Telang, N.T., Osborne, M.P. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. Ann NY Acad Sci 1999, 889: 204-13.
49. Bradshaw, T.D., Stevens, M.F.G., Westwell, A.D. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds. Curr Med Chem 2001, 8: 203-10.
50. Bradshaw, T.D., Westwell, A.D. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem 2004, 11: 1009-21.
51. Shi, D.-F., Bradshaw, T.D., Wrigley, S., McCall, C.J., Lelieveld, P., Fichtner, I., Stevens, M.F.G. Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem 1996, 39: 3375-84.
52. Bradshaw, T.D., Wrigley, S., Shi, D.-F., Schultz, R.J., Paull, K.D., Stevens, M.F.G. 2-(4-Aminophenyl)benzothiazoles: Novel agents with selective profiles of in vitro antitumour activity. Brit J Cancer 1998, 77: 745-52.
53. Bradshaw, T.D., Shi, D.-F., Schultz, R.J., Paull, K.D., Kelland, L., Wilson, A., Garner, C., Fiebig, H.H., Wrigley, S., Stevens, M.F.G. Influence of 2-(4-aminophenyl)benzothiazoles on growth of ovarian carcinoma cells in vitro and in vivo. Brit J Cancer 1998, 78: 421-9.
54. Hutchinson, I., Bradshaw, T.D., Matthews, C.S., Stevens, M.F.G., Westwell, A.D. Antitumour benzothiazoles. Part 20: 3'-Cyano and 3'-alkynyl-substituted 2-(4'-aminophenyl)benzothiazoles as new potent and selective analogues. Bioorg Med Chem Lett 2003, 13: 471-4.
55. Weinstein, J.N., Myers, T.G., O'Connor, P.M., Friend, S.H., Fornace, A.J. Jr., Kohn, K.W., Fojo, T., Bates, S.E., Rubinstein, L.V., Anderson, N.L. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275: 343-9.
56. Kashiyama, E., Hutchinson, I., Chua, M.-S., Stinson, S.F., Phillips, L.R., Kaur, G., Sausville, E.A., Bradshaw, T.D., Westwell, A.D., Stevens, M.F.G. Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl) benzothiazoles. J Med Chem 1999, 42: 4172-84.
57. Loaiza-Pérez, A.I., Trapani, V., Hose, C., Singh, S.S., Trepel, J.B., Stevens, M.F.G., Bradshaw, T.D., Sausville, E.A. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 2002, 61: 13-9.
58. Monks, A., Rivera, M.I., Harris, E., Hose, C., Sausville, E.A. Gene expression changes induced by a novel antitumor agent, 2-(4-amino-3- methylphenyl)benzothiazole, in MCF-7, a sensitive breast cancer cell line, using cDNA microarrays. Proc Amer Assoc Cancer Res 2001, 42: Abst 3417.
59. Hose, C., Rivera, M., Sausville, E.A., Monks, A. Induction of cytochrome P450CYP1A1 and cytochrome P450CYPB1 by 2-(4-amino-3-methylphenyl)benzothiazole (BZ) in 60 human tumor cell lines: Correlation with BZ toxicity. Proc Amer Assoc Cancer Res 2001, 42: Abst 2749.
60. Chua, M.-S., Kashiyama, E., Bradshaw, T.D., Stinson, S., Brantley, E., Sausville, E.A., Stevens, M.F.G. Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 2000, 60: 5196-203.
61. Stevens, M.F.G., Heydon, R.T., Martin, E.A., Farmer, P.B., Bradshaw, T.D., Hutchinson, I., Westwell, A.D., Browne, H.L., Trapani, V. Induction of CYP1A1 by 2-(4-aminophenyl)benzothiazoles leads to DNA adducts in sensitive tumor cells. Proc Amer Assoc Cancer Res 2001, 42: Abst 1754.
62. Liehr, J.G. 2-Fluoroestradiol - Separation of estrogenicity from carcinogenicity. Mol Pharmacol 1983, 23: 278-81.
63. Morgan, P., Maggs, J.L., Bulman-Page, P.C., Hussain, F., Park, B.K. The metabolism of 2-fluoro-17-β-estradiol and 4-fluoro-17-β estradiol in the rat and its implications for estrogen carcinogenesis. Biochem Pharmacol 1992, 43: 985-94.
64. Hutchinson, I., Chua, M.-S., Browne, H.L., Trapani, V., Bradshaw, T.D., Westwell, A.D., Stevens, M.F.G. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 2001, 44: 1446-55.
65. Bradshaw, T.D., Bibby, M.C., Double, J.A., Fichtner, I., Cooper, P.A., Alley, M.C., Donohue, S., Stinson, S.F., Tomaszewjski, J.E., Sausville, E.A., Stevens, M.F.G. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 2002, 1: 239-46.
66. Trapani, V., Patel, V., Leong, C-O., Ciolino, H.P., Yeh, G.C., Hose, C., Trepel, J.B., Stevens, M.F.G., Sausville, E.A., Loaiza-Pérez, A.I. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5- fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Brit J Cancer 2003, 88: 599-605.
67. Kennedy, S.W., Jones, S.P. Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescence plate reader. Anal Biochem 1994, 222: 217-23.
68. Hose, C., Hollinghead, M., Sausville, E.A., Monks, A. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5- fluorobenzothiazole: A potential surrogate marker for patient sensitivity. Mol Cancer Ther 2003, 2: 1265-72.
69. Ma, Q., Lu, A.Y.H. Origins of individual variability in P4501A induction. Chem Res Toxicol 2003, 16: 249-60.
70. Leong, C-O., Gaskell, M., Martin, E.A., Heydon, R.T., Farmer, P.B., Bibby, M.C., Cooper, P.A., Double, J.A., Bradshaw, T.D., Stevens, M.F.G. Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Brit J Cancer 2003, 88: 470-7.
71. O'Brien, S.E., Browne, H.L., Bradshaw, T.D., Westwell, A.D., Stevens, M.F.G., Laughton, C.A. Antitumor benzothiazoles. Part 23 - Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A 1. Org Biomol Chem 2003, 1: 493-7.
72. Wheelhouse, R.T., Shi, D.-F., Wilman, D.E.V., Stevens, M.F.G. Antitumour benzothiazoles. 4. An NMR study of the sites of protonation of 2-(4-aminophenyl)benzothiazoles. J Chem Soc Perkin Trans 2, 1996, (7): 1271-4.
73. Shi, D.-F., Bradshaw, T.D., Chua, M.-S., Westwell, A.D., Stevens, M.F.G. Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives. Bioorg Med Chem Lett 2001, 11: 1093-5.
74. Hutchinson, I., Jennings, S.A., Vishnuvajjala, B.R., Westwell, A.D., Stevens, M.F.G. Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 2002, 45: 744-7.
75. Pochopin, N.L., Charman, W.N., Stella, V.J. Amino acid derivatives of dapsone as water-soluble prodrugs. Int J Pharm 1995, 121: 157-67.
76. Bradshaw, T.D., Chua, M.-S., Browne, H.L., Trapani, V., Sausville, E.A., Stevens, M.F.G. In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Brit J Cancer 2002, 86: 1348-54.
77. Yamashita, Y., Kawada, S., Nakano, H. Induction of mammalian topoisomerase II delendent DNA cleavage by noninteractive flavonoids, genistein and orobol. Biochem Pharmacol 1990, 39: 737-44.
78. Ferriola, P., Cody, V., Middleton, E. Jr. Protein kinase C inhibition by plant flavonoids. Biochem Pharmacol 1989, 38: 1617-24.
79. Double, J.A., Bibby, M.C., Loadman, P.M. Pharmacokinetics and antitumor activity of LM 985 in mice bearing transplantable adenocarcinomas of the colon. Brit J Cancer 1986, 54: 595-600.
80. Beutler, J.A., Cardellina, J.H. II, Lin, C.M., Hamel, E., Cragg, G.M., Boyd, M.R., Centaureidin, A. A cytotoxic flavone from Polymnia fructicosa inhibits tubulin polymerisation. Bioorg Med Chem Lett 1993, 3: 581-4.
81. Hirano, T., Oka, K., Akiba, M. Antiproliferative effects of synthetic and naturally occurring flavonoids on tumor cells of human breast carcinoma cell line, ZR-75-1. Res Comm Chem Pathol Pharmacol 1989, 64: 69-78.
82. Akama, T., Shida, Y., Sugaya, T., Ishida, H., Gomi, K., Kasai, M. Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 1996, 39: 3461-9.
83. Griffiths, L.A. Mammalian metabolism of flavonoids. In: Flavanoids: Advanced Research. Harborne, J.B., Mabry, T.J. (Eds.). Chapman and Hall: London 1982, 681-718.
84. Ames, B.M., McCann, J., Yamasaki, E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian microsome mutagenicity test. Mutat Res 1975, 31: 347-64.
85. Akama, T., Ishida, H., Shida, Y., Kimura, U., Gomi, K., Saito, H., Fuse, E., Kobayashi, S., Yoda, N., Kasai, M. Design and synthesis of potent antitumor 5,4'-diaminoflavone derivatives based on metabolic considerations. J Med Chem 1997, 40: 1894-900.
86. Akama, T., Ishida, H., Kimura, U., Gomi, K., Saito, H. Structure-activity relationships of the 7-substituents of 5,4'-diamino-6,8,3'-trifluoroflavone, a potent antitumor agent. J Med Chem 1998, 41: 2056-67.
87. Kuffel, M.J., Schroeder, J.C., Pobst, L.J., Naylor, S., Reid, J.M., Kaufmann, S.H., Ames, M.M. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 2002, 62: 143-53.
88. Kuffel, M.J., Bowman, S.L., Browne, J.A., Reid, J.M., Naylor, S., Ames, M.M. Tumor cell- and tissue-selective cytochromes P450 oxidation of aminoflavone analog NSC 686288 (AF). Proc Am Assoc Cancer Res 2000, 41: Abst 370.
89. Kuffel, M.J., Squillance, D.P., Reid, J.M., Ames, M.M. Cytochrome P450-catalysed metabolism of the aminoflavone analog NSC 686288 in human and rat liver microsomes: The role of CYP1A subfamily enzymes. Proc Am Assoc Cancer Res 1999, 40: Abst 384.
90. Loaiza-Pérez, A.I., Vistica, D., Kennedy, S., Hose, C., Ciolino, H., Yeh, G., Trepel, J., Sausville, E.A. The aryl hydrocarbon receptor mediates sensitivity of MCF-7 cells to the antitumor agent aminoflavone NSC 686288. Clin Cancer Res 2001, 7: 413.
91. Loaiza-Pérez, A.I., Kennedy, S., Hose, C., Hollingshead, M., Alley, M., Ciolino, H., Yeh, G., Linehan, M., Vistica, D., Sausville, E.A. CYP1A1 and CYP1B1 induction and high covalent binding of metabolites are markers to predict sensitivity to aminoflavone in breast and renal cancer cells. Cancer Epidem Biomar 2002, 11: A224.